Evidence map›Paper›PMID 31080074›Full record

ArticleCell chemical biology2019

Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors.

Anja C Schlott, Stephen Mayclin, Alexandra R Reers, Olivia Coburn-Flynn, Andrew S Bell, Judith Green, Ellen Knuepfer, David Charter, Roger Bonnert, Brice Campo and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Cell chemical biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Molecules (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Exploring Subsite Selectivity withinJournal of medicinal chemistry · 2024
    Article
  8. Article
  9. Article
  10. New targets for antimalarial drug discovery.Current opinion in microbiology · 2022
    Review
  11. Review
  12. Article
  13. Review
  14. MalDA, Accelerating Malaria Drug Discovery.Trends in parasitology · 2021
    Review
  15. Review
  16. Novel Thienopyrimidine Inhibitors ofJournal of medicinal chemistry · 2020
    Article
  17. Review
  18. Article
  19. Article
  20. Wheat pathogenRSC chemical biology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Anja C SchlottFrancis Crick Institute, 1 Midland Road, London NW1 1AT, UK; Molecular Sciences Research Hub, Imperial College, White City Campus Wood Lane, London W12 0BZ, UK. Electronic address: anja.schlott@crick.ac.uk.
Stephen MayclinSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA; UCB Pharma, 7869 NE Day Road West, Bainbridge Island, WA 98110, USA.
Alexandra R ReersSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA; Center for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, USA.
Olivia Coburn-FlynnDepartment of Microbiology & Immunology, Columbia University Medical Center, New York, NY 10032, USA.
Andrew S BellMolecular Sciences Research Hub, Imperial College, White City Campus Wood Lane, London W12 0BZ, UK.
Judith GreenFrancis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Ellen KnuepferFrancis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
David CharterStructural and Biophysical Sciences, GlaxoSmithKline, Stevenage, Hertfordshire, UK.
Roger BonnertMedicines for Malaria Venture, Route de Pré-Bois 20, Post Box 1826, 1215 Geneva 15, Switzerland.
Brice CampoMedicines for Malaria Venture, Route de Pré-Bois 20, Post Box 1826, 1215 Geneva 15, Switzerland.
Jeremy BurrowsMedicines for Malaria Venture, Route de Pré-Bois 20, Post Box 1826, 1215 Geneva 15, Switzerland.
Sally Lyons-AbbottSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA; Center for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, USA.
Bart L StakerSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA; Center for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, USA.
Chun-Wa ChungStructural and Biophysical Sciences, GlaxoSmithKline, Stevenage, Hertfordshire, UK; Crick-GSK Biomedical LinkLabs, GSK Medicines Research Centre, Stevenage, UK.
Peter J MylerSeattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, WA 98109, USA; Center for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, USA; Department of Biomedical Informatics & Medical Education, University of Washington, Seattle, USA; Department of Global Health, University of Washington, Seattle, USA.
David A FidockDepartment of Microbiology & Immunology, Columbia University Medical Center, New York, NY 10032, USA; Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.
Edward W TateMolecular Sciences Research Hub, Imperial College, White City Campus Wood Lane, London W12 0BZ, UK. Electronic address: e.tate@imperial.ac.uk.
Anthony A HolderFrancis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address: tony.holder@crick.ac.uk.
Center for Infectious Disease Research · USThe Francis Crick Institute · GBMedicines for Malaria Venture · CHColumbia University Irving Medical Center · USGlaxoSmithKline (United Kingdom) · GBLondon Biofoundry · GB

Funding

Defining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4M
Structural Analysis and Inhibitor Optimization of Cryptosporidium n-myristoyltransferase for Drug DiscoveryR01AI155536 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART LEE · 2021 to 2025
$4.2M
Structural Analysis and inhibitor optimization of Cryptosporidium n-myristoyltransferase for drug discoveryR21AI137815 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART LEE · 2018 to 2019
$491k
Cancer Research UK FC001097Cancer Research UK FC010636Medical Research Council FC001097Medical Research Council FC010636NIAID NIH HHS HHSN272201700059CNIAID NIH HHS R01 AI109023NIAID NIH HHS R01 AI155536NIAID NIH HHS R21 AI137815Wellcome Trust FC001097Wellcome Trust FC010636
6 · The paper itself

Abstract

The attachment of myristate to the N-terminal glycine of certain proteins is largely a co-translational modification catalyzed by N-myristoyltransferase (NMT), and involved in protein membrane-localization. Pathogen NMT is a validated therapeutic target in numerous infectious diseases including malaria. In Plasmodium falciparum, NMT substrates are important in essential processes including parasite gliding motility and host cell invasion. Here, we generated parasites resistant to a particular NMT inhibitor series and show that resistance in an in vitro parasite growth assay is mediated by a single amino acid substitution in the NMT substrate-binding pocket. The basis of resistance was validated and analyzed with a structure-guided approach using crystallography, in combination with enzyme activity, stability, and surface plasmon resonance assays, allowing identification of another inhibitor series unaffected by this substitution. We suggest that resistance studies incorporated early in the drug development process help selection of drug combinations to impede rapid evolution of parasite resistance.

Indexed as

AcyltransferasesAmino Acid SequenceAntimalarialsEnzyme InhibitorsHumansMalaria, FalciparumPlasmodium falciparumPolymorphism, Single NucleotideProtein Processing, Post-TranslationalAcyltransferasesAntimalarialsEnzyme Inhibitorsglycylpeptide N-tetradecanoyltransferaseantimalarial targetcrystal structuredrug resistance developmentgenetic manipulationmalariamyristoylationN-myristoyltransferasePlasmodiumpost-translational modificationprotein lipidation

Identifiers

PMID31080074
PMCPMC6658617
OpenAlexW2944646757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.